{"id":6054,"date":"2026-08-10T11:13:52","date_gmt":"2026-08-10T09:13:52","guid":{"rendered":"https:\/\/fhucare.com\/?p=6054"},"modified":"2026-08-10T11:51:25","modified_gmt":"2026-08-10T09:51:25","slug":"how-to-decouple-efficacy-and-immune-side-effects-in-immunotherapies-for-cancer","status":"publish","type":"post","link":"https:\/\/fhucare.com\/fr\/event\/how-to-decouple-efficacy-and-immune-side-effects-in-immunotherapies-for-cancer\/","title":{"rendered":"How to decouple efficacy and immune side effects in immunotherapies for cancer?"},"content":{"rendered":"\n

PSCC Connect Lunch & Learn \u2013 September 10, 2026<\/strong><\/h1>\n\n\n\n

How to decouple efficacy and immune side effects in immunotherapies for cancer?<\/mark><\/strong><\/h2>\n\n\n\n

\ud83d\udcc5 September 10, 2026 \u2014 12:00 PM<\/strong>
\ud83d\udccd PSCC – 125 Rue \u00c9douard Vaillant, Villejuif, France<\/p>\n\n\n\n

Event Overview<\/strong><\/h2>\n\n\n\n

The PSCC Connect Lunch & Learn<\/a><\/strong>, organized in collaboration with FHU CARE\u00b2<\/strong>, brings together clinicians, researchers, and translational teams to explore one of the central challenges in modern immuno\u2011oncology: how to enhance antitumor efficacy while mitigating immune\u2011related toxicities<\/strong>.<\/p>\n\n\n\n

This session will feature a keynote presentation by Maxime Ilzkovitz<\/strong>, followed by a short expert briefing from Fran\u00e7ois\u2011Xavier Danlos<\/strong>, who will then transition to an applied discussion on T\u2011cell engagers<\/strong>.<\/p>\n\n\n\n

Keynote Speaker \u2014 Maxime Ilzkovitz, MD<\/strong><\/h2>\n\n\n\n

Internal Medicine Specialist, Institut Jules Bordet (Brussels)<\/strong> Active member of BiTOX \u2014 Belgian multidisciplinary immunotoxicity board<\/strong><\/p>\n\n\n\n

Maxime Ilzkovitz graduated in medicine from the Universit\u00e9 libre de Bruxelles (ULB) and is an internal medicine specialist who has spent the past three years at the Institut Jules Bordet<\/strong>, at the heart of immuno\u2011oncology care. He developed a strong interest in autoimmune diseases before focusing on the full spectrum of immune\u2011related adverse events (irAEs)<\/strong> associated with immune checkpoint inhibitors.<\/p>\n\n\n\n

At Jules Bordet, his clinical and academic activity is dedicated to building and structuring a Competence Centre for Immunotoxicity Management<\/strong>, in close collaboration with thoracic oncologists treating patients with immunotherapy. He is an active member of BiTOX<\/strong>, the Belgian multidisciplinary immunotoxicity board.<\/p>\n\n\n\n

He is now starting a PhD project on immune\u2011related adverse events<\/strong>, with a specific focus on cancer patients with pre\u2011existing dysimmune conditions.<\/p>\n\n\n\n

Synopsis:<\/strong><\/h2>\n\n\n\n